ITGR

Business Context and Reporting Period

Company: Wilson Greatbatch Technologies, Inc. (Note: Request metadata listed "Integer Holdings Corp," but the filing text identifies the registrant as Wilson Greatbatch Technologies, Inc.)
Filing Type: Form 10-K Annual Report
Period Ended: December 29, 2000
Business Overview: A leading developer and manufacturer of power sources (batteries), feedthroughs, and wet tantalum capacitors for implantable medical devices (pacemakers, ICDs). The company also manufactures commercial power sources for aerospace, oil and gas, and oceanographic applications.

Key Financial Metrics (Fiscal Year 2000)

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 23% to $97.8 million, driven by the commercial launch of wet tantalum capacitors and the acquisition of Battery Engineering, Inc. (BEI) in August 2000.
• Margin Compression: Gross margin declined to 43.3% from 48.2%. This was attributed to a higher mix of lower-margin products (medical components, commercial power sources) and start-up costs associated with new capacitor lines.
• Debt Reduction: Following an October 2000 Initial Public Offering (IPO) that raised $84.0 million in net proceeds, the company prepaid a significant portion of its senior debt. Long-term obligations dropped from $127.0 million to $31.0 million, and the debt-to-equity ratio fell from 287% to 25%.
• Profitability: The net loss narrowed significantly to $0.5 million from $2.3 million, despite an extraordinary loss of $1.6 million related to debt retirement.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• Capital Structure: In January 2001, the company restructured remaining debt into a new $60.0 million credit facility (Term Loan and Revolving Line) maturing in 2006.
• Product Development: Focus remains on rechargeable lithium-ion batteries for new medical devices (e.g., left ventricular assist devices, neurostimulators) and expanding commercial power source applications.
• Backlog: Firm backlog orders increased to $29.7 million at year-end 2000 from $16.2 million in 1999, largely due to new capacitor lines and the BEI acquisition.

Risks and Contingencies

• Customer Concentration: High dependence on two major customers: Guidant (34% of 2000 revenue) and St. Jude Medical (31% of 2000 revenue). Loss of either would materially harm operations.
• Intangible Assets: Intangible assets (goodwill, patents) totaled $104.4 million, representing 57% of total assets. Significant amortization expenses ($6.6 million expected in 2001) will impact future earnings.
• Raw Materials: Reliance on third-party suppliers for critical materials (lithium, tantalum, platinum). Price volatility and supply interruptions pose risks.
• Technology Obsolescence: Rapid technological changes in the medical device industry (e.g., ICD design changes reducing battery count) can reduce unit sales.

Investor Verification Checklist

• Customer Renewals: Verify the status of supply agreements with Guidant (expires Dec 2001) and St. Jude Medical (expires Dec 2003), as these represent 65% of revenue.
• Debt Covenants: Review the financial covenants (EBITDA, leverage ratios) in the new January 2001 credit facility to ensure compliance.
• Intangible Asset Valuation: Assess the recoverability of the $104.4 million in intangible assets, particularly given the high amortization burden.
• Raw Material Costs: Monitor pricing trends for lithium, tantalum, and platinum, which are critical inputs with limited supplier bases.
• Patent Expirations: Note that three material patents for pacemaker batteries expired in January 2001, terminating royalty payments from Medtronic.